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Objectives This retrospective multicenter registry evaluated the safety and feasibility of left ventricular (LV) support with the Im-
pella 2.5 (Abiomed Europe GmbH, Aachen, Germany) during high-risk percutaneous coronary intervention (PCI).
Background Patients with complex or high-risk coronary lesions, such as last remaining vessel or left main lesions, are in-
creasingly being treated with PCI. Because periprocedural hemodynamic compromise and complications might
occur rapidly, many of these high-risk procedures are being performed with mechanical cardiac assistance, par-
ticularly in patients with poor LV function. The Impella 2.5, a percutaneous implantable LV assist device, might
be a superior alternative to the traditionally used intra-aortic balloon pump.
Methods The Europella registry included 144 consecutive patients who underwent a high-risk PCI. Safety and feasibility
end points included incidence of 30-day adverse events and successful device function.
Results Patients were older (62% 70 years of age), 54% had an LV ejection fraction 30%, and the prevalence of co-
morbid conditions was high. Mean European System for Cardiac Operative Risk Evaluation score was 8.2 (SD
3.4), and 43% of the patients were refused for coronary artery bypass grafting. A PCI was considered high-risk
due to left main disease, last remaining vessel disease, multivessel coronary artery disease, and low LV function
in 53%, 17%, 81%, and 35% of the cases, respectively. Mortality at 30 days was 5.5%. Rates of myocardial in-
farction, stroke, bleeding requiring transfusion/surgery, and vascular complications at 30 days were 0%, 0.7%,
6.2%, and 4.0%, respectively.
Conclusions This large multicenter registry supports the safety, feasibility, and potential usefulness of hemodynamic support
with Impella 2.5 in high-risk PCI. (J Am Coll Cardiol 2009;54:2430–4) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.018d
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Ghe rapid advances in percutaneous coronary intervention
PCI) technology and refinement in adjunctive pharmaco-
ogical therapy have expanded and will continue to expand
ercutaneous treatment possibilities. Patients with complex
r high-risk coronary lesions, due to extensive and diffuse
ultivessel, left main, or last remaining coronary artery
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or PCI—are increasingly being treated with PCI (1).
urthermore, PCI is increasingly considered an alternative
o coronary artery bypass grafting (CABG) in selected
atients other than those who have been refused for cardiac
urgery.
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December 15/22, 2009:2430–4 The Europella RegistryBecause periprocedural hemodynamic compromise and
omplications can occur rapidly, a growing number of
igh-risk PCI procedures are being performed with me-
hanical cardiac assistance, particularly in patients with poor
eft ventricular (LV) function. Although, the exact role of
echanical cardiac assistance in periprocedural risk man-
gement of complex and high-risk PCI procedures remains
matter of debate, the recently introduced percutaneous left
entricular assist devices (LVADs) might be a superior
lternative to intra-aortic balloon pump (IABP) (2,3). To
ate, no large series concerning prophylactic percutaneous
VAD therapy in elective high-risk PCI have been pub-
ished. Therefore, the purpose of this study was to investi-
ate safety and feasibility of the Impella 2.5 (Abiomed
urope GmbH, Aachen, Germany), a minimally invasive
ercutaneous LVAD able to provide flow support up to 2.5
/min, in elective high-risk PCI.
ethods
tudy design. The Europella registry comprised patients
rom 10 tertiary PCI centers across Europe. It was designed
o evaluate the safety and feasibility of all patients under-
oing elective high-risk PCI with prophylactic mechanical
ardiac support with the Impella 2.5. Patients with ST-
egment elevation myocardial infarction (MI) within 48 h or
ardiogenic shock, or patients undergoing emergent PCI
ere excluded. The registry was supported by Abiomed
urope GmbH. The investigators had access to the data,
nd control of the data analysis and monitoring plan.
mpella 2.5. As described earlier, the Impella 2.5
Abiomed, Inc.) is a novel catheter-mounted (9-F) micro-
xial rotary bloodpump (12-F), designed for short-term
irculatory support. Through a femoral approach it is
ositioned across the aortic valve into the LV with fluoros-
opy. Expelling aspirated blood from the LV into the
scending aorta, the Impella 2.5 at its maximal rotation
peed of 51,000 rpm is able to provide flow up to 2.5 l/min.
he Impella 2.5 is CE (Conformité Européenne) marked
or use up to 5 days and has recently received a 510(k)
learance for partial circulatory support for periods of up to
h from the U.S. Food and Drug Administration.
ata collection. Baseline characteristics including PCI-
nd Impella-related procedural characteristics were obtained
rom pre-specified clinical report forms. In addition, vital
tatus and adverse events were collected at 30-day
ollow-up.
tudy end points and definitions. The primary safety end
oint was the incidence of major adverse cardiac and
erebral events defined as death, major bleeding requiring
ransfusion or surgery, MI, urgent CABG, or stroke at 30
ays. Secondary safety end points included device malfunc-
ion, infection, vascular complications, renal failure, and
emolysis requiring transfusion. The primary feasibility end
oint included successful deployment, operation, and ex-
lantation of the Impella 2.5. All events were based on dlinical diagnoses assigned by the
atient’s physician and were cen-
rally adjudicated by an indepen-
ent clinician.
tatistical analysis. Data are
resented as mean  SD for
ontinuous variables and as num-
er of patients and frequencies
or categorical variables. Euro-
COREs were estimated with
he online version of the Euro-
ean System for Cardiac Opera-
ive Risk Evaluation. Patients
ith an additive score sum 6
re considered at high risk.
esults
etween July 2004 and Decem-
er 2007, a total of 144 consec-
tive patients received prophy-
actic circulatory support with
mpella 2.5 during high-risk
CI. The age of patients and the
revalence of comorbid condi-
ions were high. Moreover, 54% of the patients had a left
entricular ejection fraction (LVEF) 30%. Baseline and
emodynamic characteristics are detailed in Table 1.
rocedural characteristics. All PCI cases were qualified by
he attending operators as high-risk procedures. The mean
uroSCORE was 8.2  3.4. In 43% of the cases, patients
ere refused for CABG. The procedure concerned left main
oronary artery (LMCA) PCI, last patent vessel PCI, and
omplex multivessel disease (MVD) in 52%, 17%, and 82%
f the cases, respectively. The procedural characteristics are
etailed in Table 2.
rimary and secondary safety end points. At 30 days, the
rimary safety end point was reached in 12.4% of the cases.
eath occurred in a total of 8 patients (1 intraprocedural
eath). There were no device-related deaths. MI did not
ccur, whereas stroke occurred in 1 patient during hospital
tay. Major bleeding requiring transfusion or surgery oc-
urred in 9 patients. With regard to the secondary safety end
oint, there were no cases of device malfunction. In 1
atient, an abscess developed at the groin where the Impella
.5 was inserted. Vascular complications (i.e., spurious
neurysm, fistula) and renal failure occurred in 6 and 3
atients, respectively. Hemolysis requiring transfusion oc-
urred in 1 patient.
rimary efficacy end point. Successful passage through the
emoral artery and implantation of the Impella 2.5 into the
V was achieved in all 144 patients. Both implantation and
xplantation of the Impella were considered easy or suitable
n 99% of the cases. The safety and efficacy end points are
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
EuroSCORE  European
System for Cardiac
Operative Risk Evaluation
IABP  intra-aortic balloon
pump
LMCA  left main coronary
artery
LV  left ventricle/
ventricular
LVAD  left ventricular
assist device
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
MVD  multivessel disease
PCI  percutaneous
coronary interventionetailed in Table 3.
M
f
e
c
t
d
a
r
l
r
9
a
L
D
T
i
I
e
s
r
l
t
a
t
b
a
p
r
a
c
t
p
i
b
L
B
V
m
P
V
E
*
a
2432 Sjauw et al. JACC Vol. 54, No. 25, 2009
The Europella Registry December 15/22, 2009:2430–4ortality stratified by type or extent of CAD and LV
unction. Because the myocardium at jeopardy and the
xtent of LV dysfunction are considered important indi-
ators of the risk of PCI, we stratified mortality according
o the type of CAD and LV function. Mortality at 30
ays for patients with all MVD, MVD  LVEF 40%,
nd MVD  LVEF 30% was 5.3%, 6.7%, and 5.4%,
espectively. LMCA or last remaining vessel, LMCA or
ast remaining vessel  LVEF 40%, and LMCA or last
emaining vessel  LVEF 30% was 6.7%, 8.3%, and
aseline Characteristics (n  144)Table 1 Baseline Characteristics (n  144)
Clinical characteristics and risk factors
Age (yrs) 71.8 9.9
Male 117 (81.3)
Body mass index 25 kg/m2 85 (59.0)
Hypertension 97 (67.4)
Diabetes 62 (43.1)
Current smoker 61 (42.4)
Hypercholesterolemia 93 (64.6)
Chronic obstructive pulmonary disease 26 (18.1)
Renal insufficiency 41 (28.5)
Atrial fibrillation 20 (13.9)
Peripheral vascular disease 32 (22.2)
Stroke or transient ischemic attack 20 (13.9)
Previous MI 76 (52.8)
MI within last 90 days 36 (25.0)
Previous CABG 42 (29.2)
Hemodynamic status before PCI
Heart rate (beats/min) 72.2 16.2
Systolic pressure (mm Hg) 130.0 26.2
Diastolic pressure (mm Hg) 66.8 15.4
LVEF 40% 92 (63.9)
LVEF 30% 70 (48.6)
alues are mean  SD or n (%).
CABG  coronary artery bypass grafting; LVEF  left ventricular ejection fraction; MI 
yocardial infarction; PCI  percutaneous coronary intervention.
rocedural Characteristics (n  144)Table 2 Procedural Characteristics (n  144)
PCI procedure
Time of PCI procedure (min) 114.7 55.2
Number of target lesions
1 42 (29.2)
2 47 (32.6)
3 55 (38.2)
EuroSCORE: standard 8.2 3.4
EuroSCORE: logistic (%) 15.0 12.2
Qualification for high-risk PCI
Left main coronary artery PCI 76 (52.8)
Last patent vessel PCI 25 (17.4)
Multivessel disease 118 (81.9)
Low LVEF 51 (35.4)
Other 12 (8.3)
Refused for CABG 62 (43.1)c
alues are mean  SD or n (%).
Abbreviations as in Table 1..1%, respectively. Mortality at 30 days for patients with
ll LMCA, LMCA  LVEF 40%, and LMCA 
VEF 30% was 8.3%, 10.8%, and 12%, respectively.
iscussion
his study reports on the Europella registry, which to date
s the largest cohort of patients who underwent an elective
mpella 2.5-supported high-risk PCI. The 144 patients
nrolled reflect a representative population of patients pre-
enting to PCI centers in contemporary practice for high-
isk procedures (i.e., due to complex or high-risk coronary
esions and/or multiple comorbidities).
The present study shows that periprocedural support with
he Impella 2.5 for elective high-risk PCI is safe and feasible
nd extends to encouraging findings with this novel percu-
aneous LVAD from 3 smaller case series (Table 4) (2,4,5).
There are currently many new percutaneous LVADs
eing developed, and supporters foresee that the growing
ccessibility of these devices will significantly expand the
ercutaneous treatment possibilities, particularly in high-
isk PCI. However, 2 important questions need to be
nswered. First, what is the exact indication for mechanical
ardiac assist in the setting of elective PCI? Second, what is
he optimal device to be used during elective high-risk PCI
rocedures?
First, the guidelines are conservative with regard to the
ndications of mechanical cardiac assist in elective PCI,
ecause they only recommend it in patients with very poor
V dysfunction or those considered at high risk of peripro-
nd Points at 30-Day Follow-UpTable 3 End Points at 30-Day Follow-Up
Variables All SAEs
Primary safety end point—MACCE, n (%)
Death 8 (5.5)
Bleeding requiring transfusion 8 (5.5)
Bleeding requiring surgery 1 (0.7)
MI 0 (0)
Urgent CABG 0 (0)
Stroke 1 (0.7)
Secondary safety end point, n (%)
Device malfunction 0 (0)
Infection 1 (0.7)
Vascular complication 6 (4.0)
Renal failure 3 (2.1)
Hemolysis requiring transfusion 1 (0.7)
Primary efficacy end point
Impella implantation rate—easy/suitable/difficult (%) 86.8/12.5/0.7
Impella explantation rate*—easy/suitable/difficult (%) 93.7/5.6/0.7
Impella support time (min) 87.8 50.7
n  143; 1 case not applicable due to intraprocedural death.
MACCE  major adverse cardiac and cerebral events; SAE  serious adverse event; other
bbreviations as in Table 1.edural hemodynamic collapse (6). However, is there a
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December 15/22, 2009:2430–4 The Europella Registryniform definition of high-risk PCI? The Europella registry
hows that there were several reasons for qualifying the PCI
rocedure as high-risk, thus necessitating mechanical car-
iac support according to the attending operators. Interven-
ions in an unprotected LMCA or LMCA equivalent, in a
ast patent vessel and in patients with complex coronary
VD, and low LV function were put forward to be reasons
or employing the Impella 2.5 during the PCI procedure.
hese criteria, in absence of well-defined criteria and
andomized controlled trials providing evidence for specific
ndications, are also the consensus amongst experts in the
eld (1). Of note, employment of this rationale by the
ttending operators is retrospectively supported by the sub-
roup analysis in this study with regard to the mortality
tratified by type of CAD and extent of LV dysfunction. Also
riteria concerning comorbidities of patients seemed to be
mportant in the decision to use periprocedural mechanical
upport, as shown by the high comorbidity profile of the
atients included in the Europella registry. However, co-
orbidity was not frequently addressed as the main reason
o use mechanical support. Important evidence for defining
he indications of elective periprocedural support will likely
merge from 2 ongoing multicenter randomized trials—the
ROTECT 2 (Prospective, Multicenter Randomized Con-
rolled Trial) (NCT00562016) and the BCIS 1 (Balloon-
ump assisted Coronary Intervention Study)—randomizing
etween IABP versus Impella 2.5 periprocedural support,
nd elective IABP use versus conventional treatment (bail-
ut IABP use), respectively. The first trial includes patients
ho have either MVD and an LVEF 35% or an unpro-
ected LMCA and an LVEF 30%, whereas the latter
ncludes patients with an LMCA lesion or a jeopardy score
8 and an LVEF 30%. Interestingly, the inclusion
riteria of both trials are based on the severity of LV
ysfunction and the extent of myocardium at jeopardy.
Second, although mechanical cardiac assist might be an
ppealing treatment strategy for high-risk PCI, iatrogenic
orbidity and complications due to the introduction of any
nvasive therapy should not outweigh the benefits. Cur-
ently, the most-used LV support device in elective high-
isk PCI is the IABP. Reported usage rates of the IABP
ange from 4.9% to 64%, depending on the specific case mix
f the studies. Although prophylactic IABP therapy for
lective high-risk PCI is still debated, there seems to be a
rend for improved survival when used, particularly due to a
ower periprocedural complication rate (7,8). However, the
ABP requires residual cardiac function and stable cardiac
hythm for effective use. In contrast, in safety and feasibility
tudies, percutaneous LVADs were shown to be capable of
roviding more adequate cardiac support compared with
ABP, particularly during hemodynamic depression due to
alloon inflation, in case of periprocedural emergencies such
s coronary dissection or cardiogenic shock (4,9).
The main reasons impeding widespread implementa-
tion of percutaneous LVADs for use in elective high-riskEx
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The Europella Registry December 15/22, 2009:2430–4CI and other indications were the high complication
ates and complex handling of earlier devices, such as the
emoro-femoral cardiopulmonary support system, He-
opump (Medtronic, Minneapolis, Minnesota), and the
andemheart (CardiacAssist, Pittsburgh, Pennsylvania)
1,10). Three small series of periprocedural Impella 2.5
upport were encouraging with respect to safety and
easibility (2,4,5). However to date, large series of the use
f Impella 2.5 in high-risk PCI were lacking. The
uropella registry showed that the Impella 2.5 was easy
o implant and explant, and was associated with a low rate
f adverse events. The observed mortality of 5.5% in the
egistry seems to be consistent with the rate expected for
his high-risk patient group (LMCA and/or MVD). For
omparison, the 30-day mortality was 10% in the
ROTECT I trial (4). In addition, in the SYNTAX
SYNergy Between PCI With TAXUS and Cardiac
urgery) registry for patients undergoing elective PCI,
fter being refused from CABG the 1-year mortality was
.3%. Importantly, the rate of hemorrhagic and thrombo-
mbolic complications in the Europella registry was
imited. Finally, there were no cases of device malfunc-
ion.
tudy limitations. Among others, all adverse events were
ased on clinical diagnoses assigned by the patient’s physi-
ian. However, events were entered in a prospectively
eveloped case report form and centrally adjudicated by an
ndependent clinician.
onclusions
his large multicenter registry supports the safety, feasibil-
ty, and potential usefulness of hemodynamic support with
mpella 2.5 in high-risk PCI.
cknowledgment
he authors thank Danielle Libersan for careful review ofhe paper.
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